BPC-157, TB-500 and MOTS-C come first under the interim HHS policy, with pre-orders open and shipping set for late November. The company notes the compounds aren't FDA approved.
Recap by typeshit. Full story at PR Newswire.
TIKR points to retatrutide, due for filing in early 2027, and says a pending Seventh Circuit ruling on whether it counts as a biologic could decide 5 vs 12 years of exclusivity.
She lost 7 kilos in her first month, regained it during a month-long break, and now says she's eating more and gaining in week two back.
A shared report on doctors turning to GLP-1 medications for weight loss in some kids. Details are thin, so tap through for the full story.
The author, who holds Novo shares, cites Morgan Stanley's $190 billion obesity market forecast for 2035 and an NIH-funded mouse study on aging.
Its Corexa subsidiary plans to start dispensing compounded peptide prescriptions in November 2026, citing the new HHS policy. The peptides remain unapproved.
Researchers in Denmark report pancreatic cells that naturally produce GLP-1, the hormone drugs like semaglutide are built to mimic.
Loading…